Ermium, a developer of innovative therapeutics for diseases of the immune system, primarily develops innovative therapies for autoimmune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. He is also responsible for the research of systemic lupus erythematosus, dermatomyositis, Sjögren’s syndrome, monogenic interferon disease and other diseases. Ermium Therapeutics is developing orally available drug candidates that can effectively control type 1 interferons. Recently, Ermium Therapeutics completed an additional round of financing of 6 million euros. This round of financing was led by Kurma Partners and Fountain Healthcare Partners.
This article is reproduced from: https://www.itjuzi.com/investevent/13325026
This site is for inclusion only, and the copyright belongs to the original author.